Physician profile
Ryan A Walters
NPI 1992225338
$4,192.97
in general payments reported to CMS, 2019-2025
36 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $844 · 2023: $881 · 2024: $1,114 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,114 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,114.17 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.16 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $383.13 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $375.05 | 2022-2025 | |
| Lilly USA, LLC | $329.89 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $243.19 | 2022-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $229.46 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $196.96 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $174.07 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $159.80 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $131.26 | 2021-2024 | |
| Exact Sciences Corporation | $121.65 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.80 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $113.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.88 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.89 | 2022-2025 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $92.39 | 2021-2024 | Trintellix |
| Stryker Corporation | $83.53 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Clottriever Bold Catheter |
| Janssen Pharmaceuticals, INC | $83.27 | 2022-2024 | Spravato, Xarelto |
| Corcept Therapeutics | $76.13 | 2024-2025 | Korlym |
| Sumitomo Pharma America, INC. | $72.83 | 2024-2025 | Gemtesa |
| Amgen INC. | $65.81 | 2022-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $58.27 | 2022-2025 | |
| Inari Medical, INC. | $57.91 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Daiichi Sankyo INC. | $35.94 | 2022-2025 | Injectafer |
| Tris Pharma INC | $33.72 | 2023-2025 | Dyanavel Xr |
| Boston Scientific Corporation | $33.21 | 2025 | Ams 700 |
| Xeris Pharmaceuticals, INC. | $28.38 | 2024-2025 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $22.07 | 2023 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $21.15 | 2022 | |
| Cvrx, INC. | $20.58 | 2025 | Barostim Neo System |
| Dynavax Technologies Corporation | $19.44 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $16.93 | 2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $16.53 | 2024 | Nuedexta |
| Optinose US, INC. | $14.72 | 2022 | |
| Evofem Biosciences, INC. | $13.91 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.56 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.